Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentMultilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.Isavuconazole: A New Option for the Management of Invasive Fungal Infections.EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelPrevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in AsiaIdentification by Molecular Methods and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Antifungal Susceptibility Profiles of Clinically Significant Rare Aspergillus Species in a Referral Chest Hospital in Delhi, IndIn Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderPharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisIn Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Systemic Antifungal Agents: Current Status and Projected Future Developments.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China.Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?MIC Distributions and Evaluation of Fungicidal Activity for Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Caspofungin and 20 Species of Pathogenic Filamentous Fungi Determined Using the CLSI Broth Microdilution Method.Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference LaboratoriesSusceptibility Testing of Fungi to Antifungal Drugs
P2860
Q26740837-53963480-9424-4E9D-A1AB-8C5AC6CFABBBQ26744049-449AECB0-BD50-47C4-8DFC-B63B3A53CF3DQ28067726-F273693C-6C3C-45FB-B442-9378ECB74958Q28082019-750DD071-5B3D-45E9-8D9E-58DA9F1831C6Q33622915-411AB9A0-09C4-42A9-B541-ACA1C4DFB90EQ34474946-53A14704-4D95-4070-AC72-03F9AA1114C0Q34596993-0AC2D46B-3312-445B-8FEF-B015ADEA0EE8Q35385554-17C42065-1FE1-4A21-A034-68B2B04CB091Q35585364-6C008F33-600B-445F-8BA9-7E06C153DDC6Q36076937-838AB9A4-D10C-413E-8A6D-AA11E88B78F8Q36290764-E5A7397A-7329-4ACF-ACB5-338E798EFF7AQ36439102-8A4D11AA-3368-404C-B4DC-86A0B7AF5647Q36439109-765F2E99-321A-4304-A285-68C808E610EEQ36887855-F846CC78-BF9B-4190-A786-424BF05813FBQ36977398-63C9AE92-2CBD-4512-96A8-8E8664FA4B56Q37125086-0572F51F-6B00-47C3-B45C-BC6997DEDA07Q37203893-8BB03371-9227-41A3-B275-882DC266134CQ37544819-445DEE21-B933-4FA7-A801-FAD55BEBCB0CQ38222570-233DA11E-C6F5-416E-85B6-573F077F7C45Q38285488-DEE3ECF6-6AAA-4FD0-AD2B-FFA8B9B2E64FQ38534865-81845D1B-B5DD-4A79-8B2D-B019BB77C3E0Q38644817-D4178A83-18EA-490F-9725-2B0B8F92D019Q38796140-3F33D970-26E8-47C3-809E-C11342AF5975Q38939506-3EBA1FD4-0188-4221-8B82-4E0DF52B2A51Q39364669-FEF6AF67-884F-45E1-AE6F-F8660EB19AFEQ39504883-161C6908-44A2-47F1-B81A-0F9D7FD75599Q40140001-F6123936-47C2-448A-9532-001EAED4D094Q45199703-9D1A0D12-288D-4826-8687-D704FB614ECFQ46247336-779C2721-83BC-4ED1-99C5-18752006C991Q46834709-3B8CAD64-2B25-41C1-AAE5-24CD975FC7A6Q47645128-6DCB9835-44A2-4659-8849-0383AC83640DQ49679755-DF03379B-E907-431F-ACD7-E1FFFBC5A3B2Q53779321-AB18201D-D133-4DBB-9E31-1767A4301F9CQ58701180-18791E7A-1007-44BF-B2C8-BCBB8A05A76AQ58737037-6F68DABF-4CE6-45B3-93D6-FE201264E9BC
P2860
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Multicenter study of isavucona ...... A2 broth microdilution method.
@en
type
label
Multicenter study of isavucona ...... A2 broth microdilution method.
@en
prefLabel
Multicenter study of isavucona ...... A2 broth microdilution method.
@en
P2093
P2860
P50
P356
P1476
Multicenter study of isavucona ...... -A2 broth microdilution method
@en
P2093
A Espinel-Ingroff
C Lass-Flörl
G M Gonzalez
J Turnidge
M A Pfaller
P2860
P304
P356
10.1128/AAC.00636-13
P407
P577
2013-05-28T00:00:00Z